CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN

Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More

BIG PHARMA WATCH: NOVO NORDISK LAUNCHES WEGOVY IN CHINA AT 85 PERCENT DISCOUNT COMPARED TO U.S.

Brand Name Manufacturers Continue to Charge U.S. Patients Highest Prices in… Read More

BIG PHARMA WATCH: BRAND NAME DRUG MAKER TOUTS PATENT ABUSE PLAYBOOK THAT DELAYED ACCESS TO SAFER AND MORE EFFECTIVE TREATMENTS

Gilead CEO Touts Success of Company’s Patent Playbook on HIV Portfolio That… Read More

CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE

Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More

BIG PHARMA EARNINGS WATCH: BRISTOL MYERS SQUIBB AND MERCK

Big Pharma Giants Conclude Latest Round of Earnings Reports Fueled by… Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS AND PFIZER

Big Pharma Giants Keep Beating Wall Street Expectations While Continuing to… Read More

BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN AND GSK

Big Pharma Giants Rolling in Strong Earnings While Continuing to Hike Drug… Read More

BIG PHARMA EARNINGS WATCH: ROCHE AND SANOFI

Big Pharma Giants Continue Reporting Expectation-Beating Q3 Earnings After… Read More

SECOND OPINION: BIG PHARMA ONCE AGAIN TRIES TO DEFEND THE PATENT ABUSE STATUS QUO

Eli Lilly Opinion Column Reiterates Debunked Arguments on Innovation as Brand… Read More

BIG PHARMA EARNINGS: JOHNSON & JOHNSON

Johnson & Johnson Reports Higher-Than-Expected Earnings Fueled by Price… Read More

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1 WEIGHT LOSS DRUG PRICES COULD COST MEDICARE $35 BILLION

CBO Confirms Cost of Blockbuster Obesity Drugs at Current Prices Would… Read More

DOSE OF REALITY: BRAND NAME DRUG MAKERS INCREASINGLY UTILIZING ‘USE CODES’ TO GAME PATENT SYSTEM AND BLOCK COMPETITION

STAT Analysis Finds Drug Makers Gaming FDA Orange Book Process to Further… Read More

© 2025 CSRXP- All Rights Reserved